结论恩替卡韦治疗慢性重型乙型肝炎具有较好的疗效和安全性。
Conclusion it can be concluded that Entecavir has good therapeutic efficiency and safety in the treatment of chronic severe hepatitis b.
结论TLR2和TLR4可能与慢性乙型肝炎及慢性重型乙型肝炎的发病有关。
Conclusion TLR2 and TLR4 may have a role in the pathogenesis of chronic hepatitis B and chronic severe hepatitis B.
目的研究激活诱导细胞死亡(AICD)现象在乙型肝炎慢性化和重型化机制中的意义。
ObjectiveTo study the significance of AICD(activation-induced cell death) in the pathogenesis of chronic hepatitis B and chronic severe hepatitis B.
应用推荐